Showing results (1-10 of 100) with videos related to
Sort By:
Pageof 10
Nature Reviews. Clinical Oncology|March 2, 2016
Evolving molecularly targeted therapies for advanced-stage thyroid cancersKeith C Bible, Mabel RyderHead & Neck|October 28, 2024
Pemetrexed-carboplatin salvage therapy in advanced thyroid cancersKenzie K Lee, John C Morris, Aditi Kumar, et al.Journal of the Endocrine Society|July 16, 2020
Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical CarcinomaKevin C Miller, Ashish V Chintakuntlawar, Crystal Hilger, et al.Current Opinion in Endocrinology, Diabetes, and Obesity|July 16, 2021
Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancersAnupam Kotwal, Mabel RyderJournal of the Endocrine Society|April 11, 2022
Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and ParagangliomasLauren Hassan Nelson, Harry Fuentes-Bayne, Jun Yin, et al.Expert Opinion on Investigational Drugs|September 14, 2011
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approachesPamela Jo Harris, Keith C BibleThe Journal of Clinical Endocrinology and Metabolism|March 22, 2017
Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective StudyAshish V Chintakuntlawar, Kandelaria M Rumilla, Carin Y Smith, et al.Thyroid : Official Journal of the American Thyroid Association|December 10, 2019
PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer PatientsAnupam Kotwal, Lisa Kottschade, Mabel RyderEndocrine-Related Cancer|May 18, 2016
New drugs for medullary thyroid cancer: new promises?Christine Spitzweg, John C Morris, Keith C BibleEndocrine Reviews|July 20, 2019
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and BeyondMaria E Cabanillas, Mabel Ryder, Camilo JimenezPageof 10